XL MDM2 consists of an orange-labeled probe hybridizing to the MDM2 gene region at 12q15 and a green-labeled probe hybridizing to the centromere of chromosome 12.

Probe maps for selected products have been updated. These updates ensure a consistent presentation of all gaps larger than 10 kb including adjustments to markers, genes, and related elements. This update does not affect the device characteristics or product composition.Please refer to the list to find out which products now include updated probe maps.

Probe map details are based on UCSC Genome Browser GRCh37/hg19, with map components not to scale.

The tumor suppressor gene TP53 is a key regulator in the cell cycle and is involved in apoptosis, genomic stability and angiogenesis. Inactivation of TP53 function prevents the antiproliferative effect and contributes to the development of many types of cancer. Several mechanisms of TP53 loss of function are known such as gene mutations, interaction of p53 with viral proteins and association of p53 with the MDM2 oncoprotein. MDM2 is an ubiquitin ligase negatively regulating p53. MDM2 is amplified in about 7% of all human cancers with the highest frequency of about 20% in soft tissue tumors. MDM2 might also have p53-independent transforming capabilities. Well-differentiated liposarcomas/atypical lipomatous tumors (WDL-ALT) and dedifferentiated liposarcomas are among the most common soft tissue tumors in adults. Both entities share the same genetic aberration, an amplification of the chromosomal region including MDM2. WDL-ALT and benign lipomatous tumors can be morphologically similar and a clear assignment based on histological features might be difficult. The analysis of the MDM2 amplification status by FISH is considered as a useful technique for the differential diagnosis of WDL-ALT and benign lipomatous tumors since benign lesions do not harbor MDM2 amplifications. Furthermore, MDM2 overexpression has been reported to be a potential cause of p53 dysfunction in chronic lymphoblastic leukemia.

Clinical Applications

• Chronic Lymphocytic Leukemia (CLL)

XL MDM2 hybridized to lymphocytes. Two normal interphases and one normal metaphase are shown.

• Haidar et al (1997) Am J Hematol 54:189-195
• Momand et al (1998) Nucleic Acids Res 26:3453-3459
• Weaver et al (2008) Mod Pathol 21:943-949